N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical
申请人:American Cyanamid Company
公开号:US04568687A1
公开(公告)日:1986-02-04
This disclosure describes novel N-[.omega.-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.
This disclosure describes novel N-[ω-(1H-imidazol-1-yl)alkyl]arylamides which possess the property of inhibiting the enzyme thromboxane synthetase and are also useful in the treatment of hypertension and myocardial ischemia.
Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-Imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones as unique antihypertensive agents
作者:Jeffery B. Press、William B. Wright、Peter S. Chan、Joseph W. Marsico、Margie F. Haug、Jess Tauber、Andrew S. Tomcufcik
DOI:10.1021/jm00155a036
日期:1986.5
A series of N-[(1H-heteroaryl)alkyl]-1H-isoindole-1,3(2H)-diones were prepared as part of a continuing investigation into the biological properties of compounds that were both thromboxane synthetase inhibitors and potential antihypertensive agents. The most active thromboxane synthetase inhibition was found for the title imidazole derivatives wherein a hexyl or octyl chain separated the heterocyclic ends of the molecule (5,6) or with substitution on the isoindole portion of the molecule (18, 19, 21, 22, 25, 26). Compounds with shorter alkyl chain separations had good antihypertensive effects (1-5, 8-10, 19-22, 27-30). Butyl derivative 3 was chosen for further evaluation as a potential antihypertensive agent with thromboxane synthetase inhibitory properties.
PRESS J. B.; WRIGHT W. B., JR.; CHAN P. S.; MARSICO J. W.; HAUG M. F.; TA+, J. MED. CHEM., 29,(1986) N 5, 816-819
作者:PRESS J. B.、 WRIGHT W. B., JR.、 CHAN P. S.、 MARSICO J. W.、 HAUG M. F.、 TA+